BIVI · Insider Trading
BioVie, Inc. Common Stock
Every open-market purchase and sale reported by BIVI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Cuong V Do | President & CEO | Buy | +15,210 | +$31.64K |
| 2026-08-28 | Joanne Wendy Kim | Chief Financial Officer | Buy | +2,500 | +$5.45K |
| 2026-08-28 | Amy Suzon Chappell | Director | Buy | +727 | +$1.57K |
| 2026-08-28 | Joseph M Palumbo | Chief Medical Officer | Buy | +4,843 | +$10.46K |
| 2025-01-07 | Cuong V Do | President & CEO | A | +104,502 deriv. | — |
| 2025-01-07 | Robert J Hariri | Director | A | +71,615 deriv. | — |
| 2025-01-07 | Joseph M Palumbo | Chief Medical Officer | A | +15,417 deriv. | — |
| 2025-01-07 | Joanne Wendy Kim | Chief Financial Officer | A | +14,417 deriv. | — |
| 2025-01-07 | Richard J Berman | Director | A | +34,200 | — |
| 2025-01-07 | Sigmund Rogich | Director | A | +32,700 | — |
| 2025-01-07 | James Paul Lang | Director | A | +84,290 deriv. | — |
| 2025-01-07 | Michael Edward Sherman | Director | A | +80,225 deriv. | — |
| 2024-07-12 | Cuong V Do | President & CEO | MIXED | +116,094 | −$53.04K |
| 2024-07-12 | Joseph M Palumbo | Chief Medical Officer | MIXED | +82,048 | −$30.31K |
| 2024-07-12 | Joanne Wendy Kim | Chief Financial Officer | MIXED | +49,798 | −$25.21K |
| 2024-03-06 | Cuong V Do | President & CEO | Buy | +10,000 | — |
| 2023-12-13 | Joanne Wendy Kim | Chief Financial Officer | A | +5,000 | — |
| 2023-12-06 | Robert J Hariri | Director | A | +42,254 | — |
| 2023-12-06 | Michael Edward Sherman | Director | A | +89,750 deriv. | — |
| 2023-12-06 | Richard J Berman | Director | A | +51,830 | — |
| 2023-12-06 | Steve Gorlin | Director | MIXED | −29,322 | −$127.90K |
| 2023-12-06 | James Paul Lang | Director | A | +93,500 deriv. | — |
| 2023-12-06 | Sigmund Rogich | Director | A | +42,254 | — |
| 2023-12-01 | Cuong V Do | President & CEO | Buy | +10,000 | +$17.80K |
| 2023-09-07 | Steve Gorlin | Director | Sell | −8,560 | −$26.11K |
| 2023-08-24 | Richard J Berman | Director | Sell | −10,805 | −$37.83K |
| 2023-07-03 | Joanne Wendy Kim | Chief Financial Officer | A | +20,000 deriv. | — |
| 2023-07-03 | Joseph M Palumbo | Chief Medical Officer | A | +30,000 deriv. | — |
| 2023-07-03 | Cuong V Do | CEO & President | A | +149,500 | — |
| 2023-06-26 | Cuong V Do | CEO & President | M | +41,506 | — |
| 2023-06-15 | Richard J Berman | Director | Sell | −10,984 | −$67.29K |
| 2023-04-06 | Richard J Berman | Director | Sell | −10,984 | −$93.58K |
| 2023-02-22 | Joseph M Palumbo | Chief Medical Officer | F | −2,476 | −$15.15K |
| 2023-02-22 | Joanne Wendy Kim | Chief Financial Officer | F | −2,476 | −$15.15K |
| 2023-02-22 | Cuong V Do | CEO & President | F | −4,953 | −$30.31K |
| 2023-02-22 | Clarence N. Ahlem | EVP Neuroscience Product Dev. | F | −2,476 | −$15.15K |
| 2023-02-22 | Christopher Reading | EVP Neuroscience R&D | F | −2,476 | −$15.15K |
| 2023-02-22 | Penelope Markham | EVP Liver Cirrhosis R&D | F | −2,476 | −$15.15K |
| 2023-01-18 | Joanne Wendy Kim | Chief Financial Officer | A | +39,624 | — |
| 2023-01-18 | Steve Gorlin | Director | A | +34,240 | — |
| 2023-01-18 | Christopher Reading | EVP Neuroscience R&D | A | +39,624 | — |
| 2023-01-18 | Penelope Markham | EVP Liver Cirrhosis R&D | A | +39,624 | — |
| 2023-01-18 | Sigmund Rogich | Director | A | +55,000 deriv. | — |
| 2023-01-18 | James Paul Lang | Director | A | +43,578 | — |
| 2023-01-18 | Joseph M Palumbo | Chief Medical Officer | A | +39,624 | — |
| 2023-01-18 | Cuong V Do | CEO & President | A | +79,248 | — |
| 2023-01-18 | Michael Edward Sherman | Director | A | +75,000 deriv. | — |
| 2023-01-18 | Richard J Berman | Director | A | +43,578 | — |
| 2023-01-18 | Clarence N. Ahlem | EVP Neuroscience Product Dev. | A | +39,624 | — |
| 2023-01-18 | Terren S Peizer | Director | A | +65,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cuong V Do | President & CEO | 21,636 | $28.78K |
| Joseph M Palumbo | Chief Medical Officer | 6,036 | $8.03K |
| Richard J Berman | Director | 4,064 | $5.41K |
| Sigmund Rogich | Director | 3,693 | $4.91K |
| Joanne Wendy Kim | Chief Financial Officer | 3,441 | $4.58K |
| Amy Suzon Chappell | Director | 727 | $967 |
| James Paul Lang | Director | 686 | $912 |
| Robert J Hariri | Director | 423 | $563 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BIVI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.